Major new phase in heart failure management
AHA 2015, Orlando, FL, USA
Video navigation menu
Clinical benefit of conventional inhibitors of the renin-angiotensin system (RAS). 0:01
The search for better ways to inhibit RAS. 0:32
Effects of simultaneous inhibition of RAS and neprilysin by sacubitril-valsartan (LCZ696). 1:18
Implications of the PARADIGM-HF trial for clinical practice. 2:25
Share this page with your colleagues and friends: